ENJUVIA Drug Patent Profile
✉ Email this page to a colleague
When do Enjuvia patents expire, and when can generic versions of Enjuvia launch?
Enjuvia is a drug marketed by Aspen and is included in one NDA.
The generic ingredient in ENJUVIA is estrogens, conjugated synthetic b. There are three drug master file entries for this compound. Additional details are available on the estrogens, conjugated synthetic b profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ENJUVIA?
- What are the global sales for ENJUVIA?
- What is Average Wholesale Price for ENJUVIA?
Summary for ENJUVIA
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Clinical Trials: | 2 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ENJUVIA |
| What excipients (inactive ingredients) are in ENJUVIA? | ENJUVIA excipients list |
| DailyMed Link: | ENJUVIA at DailyMed |
Recent Clinical Trials for ENJUVIA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Duramed Research | Phase 4 |
| Duramed Research | Phase 3 |
US Patents and Regulatory Information for ENJUVIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-001 | Dec 20, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-005 | Apr 27, 2007 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-002 | Dec 20, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-003 | May 10, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-004 | May 10, 2004 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENJUVIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-005 | Apr 27, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-001 | Dec 20, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-002 | Dec 20, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-004 | May 10, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-003 | May 10, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-002 | Dec 20, 2004 | ⤷ Sign Up | ⤷ Sign Up |
| Aspen | ENJUVIA | estrogens, conjugated synthetic b | TABLET;ORAL | 021443-005 | Apr 27, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ENJUVIA
See the table below for patents covering ENJUVIA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 0168669 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 0168074 | ⤷ Sign Up | |
| Germany | 60131253 | ⤷ Sign Up | |
| Austria | 377605 | ⤷ Sign Up | |
| Australia | 2001245417 | ⤷ Sign Up | |
| South Korea | 20030064614 | ⤷ Sign Up | |
| South Korea | 100804224 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
